The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.
April 11th 2024
Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Novel Combination Regimens Strengthen and Expand Treatment Paradigm for Genitourinary Cancers
January 10th 2023Tanya B. Dorff, MD, highlights improvements in the current treatment paradigm for other genitourinary cancers and spotlights efforts being made to expand the role of immunotherapy and targeted therapy combinations.
Triplet Combinations Could Represent Next Frontier in Frontline Metastatic RCC
Michael R. Harrison, MD, discusses the key long-term data of select doublet combinations in renal cell carcinoma, the early investigation of triplet therapy in the frontline setting, and more.
Pembrolizumab Appears Safe Across Melanoma, NSCLC, RCC in Pooled Analysis
Pembrolizumab induced treatment-related adverse effects that were generally mild or moderate in severity, according to finding from a pooled analysis of more than 4000 patients with melanoma, non–small cell lung cancer, or renal cell carcinoma.
FDA Grants Fast Track Designation to Batiraxcept for Advanced or Metastatic Clear Cell RCC
The FDA has granted a fast track designation to batiraxcept for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma who have progressed after 1 or 2 prior lines of systemic therapy that include both immuno-oncology–based and VEGF TKI–based therapies, either in combination or sequentially.
PROSPER-RCC Results May Inform Further Research on Neoadjuvant IO Approaches in RCC
November 29th 2022Mohamad Allaf, MD, discusses innovative and unique aspects of the PROSPER-RCC trial design, areas for continued analysis within the study, and the ways in which this trial will inspire and inform continued research in renal cell carcinoma.
ARRY-614 Plus Immune Checkpoint Inhibition Can Induce Durable Responses in Advanced Solid Tumors
The combination of the p38 MAPK inhibitor ARRY-614 plus nivolumab with or without ipilimumab was well tolerated and elicited disease control in high-risk, PD-(L)1–refractory patients with advanced solid tumors.
ADCs Represent One of Many Improvements in GU Cancer Treatment
Daniel J. George, MD, discusses the impact that ADCs have had on the evolving treatment landscape of bladder cancer, long-term outcomes with immunotherapy in metastatic renal cell carcinoma, and highlighted current and ongoing research at the Duke Cancer Institute.
CTX130 Allogeneic CAR T-cell Therapy Shows Tolerability, Intriguing Activity in Advanced RCC
CTX130, an investigational allogeneic, CRISP/Cas9 gene-edited, anti-CD70 CAR T-cell therapy, was found to be safe with early signs of clinical activity in patients with advanced clear cell renal cell carcinoma, according to findings from the phase 1 COBALT-RCC trial.
Nivolumab/Ipilimumab Plus CBM588 Generates Superior Efficacy in Metastatic RCC
The addition of CBM588 to the combination of nivolumab and ipilimumab produced superior response rates and a progression-free survival benefit vs nivolumab plus ipilimumab alone in previously untreated patients with metastatic renal cell carcinoma.